Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) EPS (Basic) (2021 - 2026)

MoonLake Immunotherapeutics' EPS (Basic) history spans 6 years, with the latest figure at -$0.98 for Q1 2026.

  • Quarterly EPS (Basic) fell 55.56% to -$0.98 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.87 through Mar 2026, down 68.26% year-over-year, with the annual reading at -$3.53 for FY2025, 86.77% down from the prior year.
  • EPS (Basic) came in at -$0.98 for Q1 2026, down from -$0.92 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.1 in Q4 2023 to a low of -$3.17 in Q1 2022.
  • The 5-year median for EPS (Basic) is -$0.43 (2022), against an average of -$0.67.
  • The largest YoY upside for EPS (Basic) was 93.71% in 2022 against a maximum downside of 31600.0% in 2022.
  • MoonLake Immunotherapeutics' EPS (Basic) stood at -$0.43 in 2022, then soared by 76.74% to -$0.1 in 2023, then tumbled by 620.0% to -$0.72 in 2024, then dropped by 27.78% to -$0.92 in 2025, then decreased by 6.52% to -$0.98 in 2026.
  • Per Business Quant, the three most recent readings for MLTX's EPS (Basic) are -$0.98 (Q1 2026), -$0.92 (Q4 2025), and -$1.1 (Q3 2025).